OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Orchestra BioMed Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.65+0.20 (+3.67%)
Close on Oct 19, 2026
- Market cap
- $360.54M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.33 (+70.18%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Orchestra BioMed Holdings, Inc. grew revenue 986.1% to $31.98M over the twelve months to Jun 30, 2026. Free cash flow was -$59.10M.
Revenue
$31.98M
+986.1% vs. a year earlier
Operating income
-$57.99M
TTM Q2 2026
Free cash flow
-$59.10M
TTM Q2 2026
EPS, diluted
-$1.01
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $360.54M
- P/E ratio
- –
- Price to sales
- 11.28
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -16.39%
Fundamentals
- Revenue
- $31.98M
- Net income
- -$59.03M
- EPS, diluted
- -$1.01
- Free cash flow
- -$59.10M
- Diluted shares
- 64M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
$31.98M+986.1% YoY
Gross profit
$31.82M+1066.4% YoY
Operating income
-$57.99M
Net income
-$59.03M
EPS, diluted
-$1.01
Free cash flow
-$59.10M
Reported periodTrailing twelve months